Stock Analysis
Revolution Medicines, Inc. (RVMD) Stock Analysis
Revolution Medicines, Inc. (RVMD) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Revolution Medicines, Inc. (RVMD) currently has an AIQ Score of 55/100, indicating a neutral setup. Momentum is the strongest factor at 73/100. Value is the weakest current factor at 39/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
RVMD at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $172.29 |
| AIQ Score | 55/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $37.03B |
| P/E Ratio (TTM) | -18.83 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$1.90 |
| Revenue (Q3 FY2026) | $197.56M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.3 |
| Volume | 2.65M |
| 52-week range | $63.50-$224.31 |
| RSI 14 | 39.68 |
| 50-Day SMA | $194.46 |
| 200-Day SMA | $159.88 |
| Analyst Price Target | $262.36 |
| Next Earnings | Feb 24, 2027 |
RVMDRevolution Medicines, Inc.
Healthcare / Biotechnology
Low Priority
In Line With Peers
Latest quote
- Momentum73
- Value39
- Quality43
- Risk resilience59
- Sentiment—
RVMD Stock Analysis Summary
Revolution Medicines, Inc. (RVMD) currently has an AIQ Score of 55/100, indicating a neutral setup. Momentum is the strongest factor at 73/100. Value is the weakest current factor at 39/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, RVMD has AIQ Score of 55/100 with Momentum base of 73/100 and fading Value at 39/100. Wait for component alignment before adding exposure.
Momentum (73/100) leads while Value (39/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -2.30% stock move · RVMD classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is RVMD Bullish or Bearish Right Now?
RVMD currently has a neutral overall setup. Momentum is the strongest factor at 73/100, while Value is weakest at 39/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Momentum is constructive at 73/100.
- - Analyst target implies +52.28% upside from the latest quote.
- - Value is the current constraint at 39/100.
- - Technical consensus has more sell votes than buy votes (35 vs 8).
Current Consensus
RVMD's Technical Analysis Consensus is currently Strong Sell, with 8 buy, 3 neutral, and 35 sell votes. RVMD's 14-day RSI is 39.68, which places the stock in a weaker momentum range. RVMD's beta is 1.3, indicating greater market sensitivity than the broad market.
What Changed in RVMD?
The largest recent change in RVMD is Momentum moving down by 6.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the RVMD Outlook?
The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
RVMD Decision Framework
Public evidence layers, setup checks, and risk context for Revolution Medicines, Inc..
Revolution Medicines, Inc. (RVMD) Stock Analysis
Revolution Medicines, Inc. has an AIQ Score of 55/100 in a Neutral regime. Momentum is strongest at 73/100. Beta is 1.3, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | RVMD is in a Neutral AIQ regime with score 55/100. |
| Signal Conflict | The primary conflict is that momentum leads at 73/100 while value lags at 39/100. |
| Factor Evidence | Momentum 73/100 · Value 39/100 · Quality 43/100 · Risk 59/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 73/100.
Momentum is 73/100 and RSI (14) is 39.7.
RVMD is in a Neutral regime at 55/100.
Risk factor is 59/100 with beta 1.3 and annual volatility 68.69%.
Current conflict: momentum leads at 73/100 while value lags at 39/100.
RVMD Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
RVMD Fundamentals
RVMD valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
RVMD Technical Analysis
RVMD technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
RVMD Stock Catalysts
Track RVMD earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
RVMD Dividend Analysis
RVMD dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
RVMD Financial Data
RVMD revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
RVMD Risk Analysis
RVMD volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
RVMD Stock News
RVMD stock news, market tone, recent headlines, and catalyst context.
RVMD vs Biotechnology Peers
Current peer cohort: RVMD · RYTM · SEPN · SLS · SMMT. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| RVMD Current stock | 55/100 | 39/100 | 73/100 | 59/100 | 1.69 | 68.69% | Current |
| RYTM Rhythm Pharmaceuticals, Inc. | 62/100 | 52/100 | 72/100 | 57/100 | 0.52 | 54.57% | RVMD vs RYTM |
| SEPN Septerna Inc | 69/100 | 55/100 | 87/100 | 52/100 | 1.43 | 69.35% | RVMD vs SEPN |
| SLS SELLAS Life Sciences Group, Inc. | 57/100 | — | 55/100 | 32/100 | 2.04 | 109.89% | RVMD vs SLS |
| SMMT Summit Therapeutics Inc. | 47/100 | — | 65/100 | 38/100 | -0.01 | 75.92% | RVMD vs SMMT |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for RVMD: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching RVMD
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for RVMD
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
RVMD Stock FAQ
What is RVMD stock price today?
Revolution Medicines, Inc.'s current stock price is $172.29. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is RVMD bullish or bearish right now?
RVMD's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is RVMD's market cap?
RVMD's market cap is $37.03B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is RVMD's current P/E ratio?
RVMD's current P/E ratio is -18.83 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is RVMD's RSI?
RVMD's 14-day RSI is 39.68 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is RVMD above its 50-day and 200-day moving averages?
RVMD is -11.40% from its 50-day SMA and 7.76% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is RVMD's next earnings date?
RVMD's next earnings date is currently listed as Feb 24, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does RVMD pay a dividend?
RVMD's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.